RxDoctor Payments Data

Kashyap Patel, MD

Clinical Neurophysiology · Statesboro, GANPI 1700947231

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $141,000 of the $199,387 with a category attached, or 70.7%. 57 manufacturers reported payments, led by AbbVie at 56.7% of the total. Reporting peaked in 2021 at $83,163 and has fallen 97.6% since, to $2,014 in 2025.

$199,387in general payments, 2019–2025

Across 1,202 payments — averaging $165.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$113K
  • Biohaven Pharmaceutical Holding Company Ltd.$24K
  • Biohaven Pharmaceuticals, Inc.$23K
  • Impel Pharmaceuticals Inc.$14K
  • Teva Pharmaceuticals USA, Inc.$8K
  • Livanova USA, Inc.$2K
  • plus $15K from 51 others
$584in research payments, 2019–2025

Across 1 payment — averaging $584.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$584

What the payments were for

  • Consulting fees$23,24612%
  • Speaking & faculty fees$141,00071%
  • Travel & lodging$11,7246%
  • Food & beverage$23,26712%
  • Education$1490%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)277$113,075
Biohaven Pharmaceutical Holding Company Ltd.33$23,586
Biohaven Pharmaceuticals, Inc.51$22,762
Impel Pharmaceuticals Inc.32$14,168
Teva Pharmaceuticals USA, Inc.82$8,435
Livanova USA, Inc.17$2,213
Novartis82$1,622
Amgen55$1,000
UCB, Inc.45$942
Eisai Inc.43$933
Neurelis, Inc.37$750
EMD Serono, Inc.25$722
Scilex Pharmaceuticals Inc.33$677
SK Life Science, Inc.33$670
Genentech USA, Inc.31$656
Pfizer31$634
Lilly USA, LLC37$600
Catalyst Pharmaceuticals, Inc.25$585
Kyowa Kirin, Inc.23$410
Sanofi7$363
Adamas Pharmaceuticals, Inc.19$354
Johnson & Johnson(2 entities)10$334
Argenx US, Inc.15$303
Jazz Pharmaceuticals Inc.11$289
AstraZeneca13$275
Lundbeck LLC13$267
Sunovion Pharmaceuticals Inc.12$252
Biogen14$249
Tanabe Pharma America, Inc.14$246
Neurocrine Biosciences, Inc.10$218
TG Therapeutics, Inc.5$193
Sumitomo Pharma America, Inc.9$179
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)3$165
E.r. Squibb & Sons, L.L.C.3$156
Avanir Pharmaceuticals, Inc.6$108
Banner Life Sciences, LLC6$104
Upsher-smith Laboratories LLC4$85
CSL Behring3$82
Otsuka America Pharmaceutical, Inc.4$82
Sobi, Inc1$70
Bristol Myers Squibb4$68
Acadia Pharmaceuticals Inc4$67
Boston Scientific3$63
Averitas Pharma Inc.2$54
Regeneron Healthcare Solutions, Inc.1$48
Bausch Health US, LLC2$46
Supernus Pharmaceuticals, Inc.2$33
Impel Pharmaceuticals LLC1$25
Azurity Pharmaceuticals, Inc.1$24
Amarin Pharma, Inc.1$23
Vivus LLC1$22
Aprecia Pharmaceuticals, LLC1$21
Saol Therapeutics Inc.1$18
MDD US Operations, LLC1$17
Grifols USA, LLC1$16
GSK1$15
GE HealthCare1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$166,701
Medicare patients
349
Services billed
1,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab53$478,148
Nurtec OdtRimegepant Sulfate200$382,660
IngrezzaValbenazine Tosylate15$201,761
UbrelvyUbrogepant104$180,426
AustedoDeutetrabenazine24$167,941
Plegridy PenPeginterferon Beta-1a17$145,239
Ajovy AutoinjectorFremanezumab-Vfrm148$118,031
BotoxOnabotulinumtoxina74$98,661
Emgality PenGalcanezumab-Gnlm124$90,039
QuliptaAtogepant59$66,268
Ajovy SyringeFremanezumab-Vfrm55$38,703
ZtlidoLidocaine85$32,919
VimpatLacosamide42$31,748
Aimovig AutoinjectorErenumab-Aooe42$30,162
ProvigilModafinil11$25,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$634$382,660200 claims
AbbVieUbrelvy, Botox, Qulipta$113,075$345,355237 claims
Neurocrine Biosciences, Inc.Ingrezza$218$201,76115 claims
Teva Pharmaceuticals USA, Inc.Austedo$8,435$167,94124 claims
Scilex Pharmaceuticals Inc.Ztlido$677$32,91985 claims
UCB, Inc.Vimpat$942$31,74842 claims
Eisai Inc.Fycompa$933$18,97815 claims
Sunovion Pharmaceuticals Inc.Aptiom$252$15,75212 claims
SK Life Science, Inc.Xcopri$670$12,20511 claims
Upsher-smith Laboratories LLCTopiramate$85$2,032284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →